C.D.L. Pharma S.A.S
C.D.L. Pharma S.A.S is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Across 16 sites in six countries, 13 participants were enrolled: France enrolled 7, Finland and Germany enrolled 2 each, Australia and Japan enrolled 1 each, and five United States sites enrolled none.
- The study terminated during Phase 1 Arm A; Phase 1 Arm B dose escalation and Phase 2 dose expansion were not initiated.
- Two participants (15.4%) were excluded from the DLT-evaluable set because they permanently discontinued treatment before completing the DLT-assessment period for reasons other than study treatment-related toxicity.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase Ib/II first-in-human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of intrathecal S230815 in paediatric participants with KCNT1-related Developmental and Epileptic Encephalopathy
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
A phase 1/2, open label, multicenter clinical trial investigating the safety, tolerability, pharmacokinetics, and antineoplastic activity of S095035 (MAT2A inhibitor) as a single agent and in combination in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for C.D.L. Pharma S.A.S?
The 2026-10-09 snapshot links C.D.L. Pharma S.A.S to 4 distinct CTIS trials. Recorded services include Laboratory services, Logistic Platform, Logistical platform. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for C.D.L. Pharma S.A.S?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Haematological Malignancies, Neurology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to C.D.L. Pharma S.A.S conducted?
The linked trials record locations in 7 countries, including France, Spain, Germany, Denmark, Italy. These are trial locations, not confirmed office locations or countries where C.D.L. Pharma S.A.S delivered services.
What can this page tell me about C.D.L. Pharma S.A.S's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under C.D.L. Pharma S.A.S. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- C.D.L. Pharma S.A.S.